Amgen must be happy. KRAS inhibitors have been a recent target recently, notably for NSCLC: https://en.wikipedia.org/wiki/Sotorasib https://en.wikipedia.org/wik

Amgen must be happy. KRAS inhibitors have been a recent target recently, notably for NSCLC: https://en.wikipedia.org/wiki/Sotorasib https://en.wikipedia.org/wiki/Sotorasib I should note that not all cancer cells exhibit KRAS mutations, so if this ARS1620 can get cancer cells to express more KRAS mutations (if biopsy shows KRAS mutations exist), now we have something to target. Reminds me of other therapies that need some type of expression on the cancer cells to enhance inhibotrs, like using the cowpea mosaic virus, TROP2, PIK3 expressions. I think this is where immunotherapy is going next, to take an expression, force cells to over express it (specific mutations that healthy cells rarely have), then bind inhibitors to target the cell for apoptosis. https://ucsdnews.ucsd.edu/pressrelease/researchers-shed-light-on-why-a-certain-plant-virus-is-so-powerful-at-fighting-cancer https://ucsdnews.ucsd.edu/pressrelease/researchers-shed-ligh... https://en.wikipedia.org/wiki/Phosphoinositide_3-kinase_inhibitor https://en.wikipedia.org/wiki/Phosphoinositide_3-kinase_inhi...